Oncolytics Biotech Inc T.ONC

G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

[Noteable]

Testing treatments for advanced pancreatic cancer

New treatments for metastatic pancreatic cancer that are being investigated in clinical trials include immunotherapy and targeted therapy. Immunotherapy uses substances to stimulate or suppress the immune system to help the body fight cancer. Targeted therapy uses drugs or other substances to target specific molecules that cancer cells need to survive and spread.

• Targeted therapies
  • Ras-directed therapies. The RAS genes makes proteins that take part in signaling pathways that control cell growth. Altered forms of these genes are found in more than 90% of pancreatic cancers. Drugs that target mutant forms of RAS are now being tested. One example is a drug that targets a form of RAS that  has a mutation called G12C and another drug that targets a more common mutation, G12D. 

https://www.cancer.gov/types/pancreatic/research

More than half the CRC patients that responded to pelareorep had either a G12V or a G12D mutation (exon 2, codon 12, KRAS gene).

https://aacrjournals.org/mct/article/19/5/1148/274337/Elucidation-of-Pelareorep-Pharmacodynamics-in-A

Pelareorep (Reolysin) is an unmodified oncolytic reovirus, delivered intravenously, that can induce a T-cell inflamed phenotype in pancreatic ductal adenocarcinoma. In a phase Ib study in patients who had progressed after first-line treatment, pelareorep, pembrolizumab, and 5-fluorouracil, irinotecan, or gemcitabine did not add significant toxicity and showed encouraging efficacy.  ( https://pubmed.ncbi.nlm.nih.gov/31694832/ )

https://ascopubs.org/doi/full/10.1200/EDBK_389072

[Noteable]

Should read: G12D/G12V KRAS mutation in PC & CRC patients respond to Pelareorep The KRAS protein normally acts like an on–off switch. In response to certain signals, it becomes activated and tells the cell to grow and divide. When the signals are no longer present, it turns off. However, some mutant forms of KRAS, such as KRAS G12D, remain active even in the absence of growth signals

[Noteable]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749787/

[Noteable]

Mutations in both KRAS and TP53 genes are found in around 80% and 70% of all human pancreatic cancers respectively. Mutant KRAS, found in 95% of pancreatic cancers, leads to an activated protein that aberrantly triggers many downstream signaling pathways. Mutant TP53 results in the loss of the proteins’ tumor suppressor function, leaving the mutant protein capable of fueling

[Noteable]

Preconditioning of the tumor microenvironment (TME) with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy - Christianne Groeneveldt et al. Results Replication-competent reovirus induced an early interferon signature, followed by a strong influx of natural killer cells and CD8+ T cells, at the cost of FoxP3+ Tregs. Viral replication declined after 7

[Noteable]

Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer-related deaths in the United States and for patients with unresectable disease, treatment options are currently limited and lack curative potential. Preclinical KPC models and its variants of PDAC that recapitulate the biology of human pancreatic cancer offer an opportunity for the rational development of novel treatment approaches

[13X2413]

Really? Interesting, but can you keep directly focused on ONC. 

[Noteable]

This post has been removed in accordance with Community Policy

[Noteable]

This post has been removed in accordance with Community Policy

[13X2413]

This post has been removed in accordance with Community Policy

[Noteable]

This post has been removed in accordance with Community Policy

[13X2413]

This post has been removed in accordance with Community Policy

[Noteable]

Try following the bouncing ball 13x2413 (you) loser. But maybe that is way too much ask from someone like you.

[Noteable]

“The KPC mouse model of pancreatic cancer is highly resistant to every drug that has been tested, very much like the human disease,” said Ben Stanger, M.D., Ph.D., of the University of Pennsylvania Abramson Cancer Center.  Yet Christianne Groeneveldt et. al and others are demonstrating pelareorep in combination with other I/O agents are effective against this

[Noteable]

ONCYs pelareorep demonstrates to be effective in the knockdown of both KRAS (G12D/G12V KRAS mutations) and p53 gene activity, and ultimately effective in the treatment of pancreatic and GI cancers. All the pre-clinical and clinical work on pelareorep in pancreatic, GI, and breast cancers. is now coming to fruition.

[fasttrack5]

Exactly why I picked up another 2000 shares at this level. Cheers.:) RJ

[Buckhenry]

To early to buy. Wait for fire sale when there is no news this week. 

[Noteable]

November 21, 2023 - Timothy Yap, Ph.D., used to see patients nearing the end of their cancer journey in his phase 1 department at the University of Texas' MD Anderson Cancer Center. Either they fit into a phase 1 trial, or they were off to hospice for end-of-life care. Things have changed, and the situation at his department is a little more hopeful nowadays. “What's interesting

[Noteable]

April 03, 2024 - Madeleine Armstrong - Merck (MSD) makes haste to catch up in KRAS " Merck & Co might be a latecomer to KRAS inhibition, but it clearly wants to make up for lost time. Less than six months after reporting first human data, the group has moved its G12C inhibitor MK-1084 into a phase 3 trial in first-line non-small cell lung cancer. The move sets up the prospect of

[Noteable]

If I was able to figure out pelareorep's MOA in pancreatic and CRC cancer  ... I am sure that Big Pharma has also, which leads me to believe that it's all about the offer price for ONCY.  The first offer should trigger a succession of other bids, and rest will be history in the acquisition of ONCY.

[Noteable]

An added benefit is that G12D and G12V KRAS mutations can be used as biomarkers to identify PC & CRC patients using next generation and single-cell sequencing. https://nanocellect.com/blog/next-generation-sequencing-and-single-cell-technology-whats-the-difference/#:~:text=However%2C%20one%20easy%20distinction%20is,DNA%20or%20RNA%20sequencing%20analysis).

[Noteable]

Having identified G12D and G12V KRAS mutations as biomarkers responsive to pelareorep in pancreatic and colorectal cancers, ONCY will be able to submit this biomarker data in their application for Accelerated Approval in both these cancers .  Single-Cell Applications of Next-Generation Sequencing   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771363/

[Noteable]

October 08, 2021 - Mirati/Sanofi announcement to collaborate. Mirati Therapeutics, the little biotech is teaming up with French pharma giant Sanofi, wedding its experimental KRAS inhibitor adagrasib with Sanofi’s investigational SHP2 inhibitor SAR442720 in patients who have already had some treatment in KRAS G12C-positive non-small lung cell cancers (NSCLCs) . SHP2, the tyrosine phosphatase

[jh1970]

Mirati Therapeutics, the little biotech. Not so little, market cap $4.2 billion. ONC is the little biotech company.

[fox7mf]

Oncy has a man at the helm who gives every indication he doesn't give two wtv's about the shareholder, cares too much about personal glory & will not sell anytime soon.

[Lesalpes29]

If it's true, I don't think Parsons and Rigby will stay very long as directors. Let's go Matt, enough of your false 'creation value for all shareholders'. Time to show the true one. GL

[Buckhenry]

This stock reminds me of the movie.. ground hog day... the same thing happens everyday.  

[13X2413]

Noteable is right, this stock is undervalued and getting more so everyday. Just like my portfolio. 

[JohnnyYeg]

Foxy - remember that PanCAN signed us on for a reason, and THEN gave us another cash injection for an additional arm. THEY have done their due diligience and if there were any indications that Matt or mgmt were pissing around, they would have passed us by. On this road with ONCY, patience is truly a virtue (you've read some of my rants recently lol) but as hard as it is for me perosnlly